Jupiter Asset Management Ltd. Makes New Investment in Humana Inc. $HUM

Jupiter Asset Management Ltd. purchased a new position in shares of Humana Inc. (NYSE:HUMFree Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 147,477 shares of the insurance provider’s stock, valued at approximately $37,773,000.

Other hedge funds also recently modified their holdings of the company. Montag A & Associates Inc. increased its stake in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after acquiring an additional 94 shares in the last quarter. CoreCap Advisors LLC grew its position in Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Rosenberg Matthew Hamilton grew its position in Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after purchasing an additional 68 shares during the period. Larson Financial Group LLC grew its position in Humana by 114.1% in the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock valued at $40,000 after purchasing an additional 81 shares during the period. Finally, Fulcrum Asset Management LLP acquired a new stake in Humana in the 3rd quarter valued at $42,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $308.41 on Friday. The firm has a 50 day moving average of $229.25 and a 200-day moving average of $228.50. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $315.66. The firm has a market capitalization of $37.03 billion, a P/E ratio of 32.99, a price-to-earnings-growth ratio of 2.22 and a beta of 0.68.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. During the same period last year, the business earned $11.58 earnings per share. Humana’s revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, sell-side analysts predict that Humana Inc. will post 9.01 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Friday, June 26th. Humana’s dividend payout ratio is 37.86%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group lifted their price objective on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a report on Thursday, April 30th. Wolfe Research lowered shares of Humana from a “strong-buy” rating to a “peer perform” rating in a research report on Wednesday, May 20th. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Weiss Ratings restated a “sell (d+)” rating on shares of Humana in a research report on Tuesday, April 21st. Finally, Oppenheimer upgraded shares of Humana from an “outperform” rating to an “outperform” rating in a research report on Wednesday, May 20th. Nine equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $270.48.

Check Out Our Latest Analysis on HUM

About Humana

(Free Report)

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Featured Articles

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.